In this week’s video, Dr. Brian GM Durie talks about benefits and risks of the combination therapies of Kyprolis and dexamethasone (Kd), and Kyprolis, Revlimid, and dexamethasone (KRd).

BOTTOM LINE:
Kyprolis as a doublet or as a triplet is an excellent option, but work with your doctor to monitor its possible side effects.

Have a question? Submit it to [email protected]

IMF Chairman Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to [email protected]!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at [email protected]


Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

Previous Post
Can New Gene-Editing Tools Provide the Roadmap to A Cure for Myeloma?
Next Post
How Gene Editing Can Help Lead to a Cure (Part Two) and the 2017 Nobel Prizes for Science

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.